GlaxoSmithKline will this week name Sir Philip Hampton as its next chairman in a move that sees him swap his role as chairman of Royal Bank of Scotland for another of the most challenging jobs in British business.
The appointment comes days after GSK was fined almost £300m by Chinese authorities for bribery and two months after a profits warning exposed broader difficulties for the UK’s biggest drugmaker.
Sir Philip will join the GSK board as a non-executive director in January and take over as chairman from Sir Christopher Gent later in the year, according to people familiar with the matter.
您已閱讀38%（597字），剩餘62%（973字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。